<DOC>
	<DOC>NCT02069496</DOC>
	<brief_summary>This post-marketing surveillance study is designed to collect safety information such as post-vaccination adverse events and adverse reactions from recipients of Arepanrix® (H1N1) Intramuscular Injection. The following items will be investigated as priority investigation items. &lt;Priority investigation items&gt; 1. Allergic reactions 2. Anaphylaxis</brief_summary>
	<brief_title>Drug Use Investigation for Arepanrix® (H1N1)</brief_title>
	<detailed_description />
	<criteria>Subjects who receive Arepanrix® intramuscular injection for the first time</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>